Skip to main content
NAC Logo NAC Logo (English) NAC Logo (Français)
National Advisory Committee on Blood and Blood Products (NAC)
  • EN
  • FR
  • Blood Shortage
  • Endorsements
  • Guidelines & Recommendations
    • COVID-19 Pandemic Resources
    • Blood Component Transfusion Recommendations
    • Plasma Protein and Related Products Recommendations
    • Special Testing / Modification Recommendations
    • Adverse Event Recommendations
  • Links & Resources
NAC Logo NAC Logo (English) NAC Logo (Français)
National Advisory Committee on Blood and Blood Products (NAC)

Main navigation

  • Blood Shortage
  • Endorsements
  • Guidelines & Recommendations
    • COVID-19 Pandemic Resources
    • Blood Component Transfusion Recommendations
    • Plasma Protein and Related Products Recommendations
    • Special Testing / Modification Recommendations
    • Adverse Event Recommendations
  • Links & Resources
  • EN
  • FR
Guidelines and Resources

You are here

  • Home
  • Guidelines & Recommendations

Guidelines & Recommendations

COVID-19 Pandemic Resources

  • Infection Prevention and Control Considerations for Return of Blood Components and Products to Inventory
  • NAC IP & C Considerations: Appendix A COVID

Blood Component Transfusion Recommendations

  • Massive Transfusion Consensus Conference
  • NAC Companion Document to: “Red Blood Cell Transfusion: A Clinical Practice Guideline from the AABB”
  • NAC Patient Blood Management Statement
  • NAC Recommendations for Solvent Detergent Plasma (S/D Plasma)
  • NAC Statement on Perioperative Autologous Blood Donation
  • NAC Statement on the Introduction of Leukocyte Reduced Whole Blood in Canada
  • National Advisory Committee (NAC) on Blood and Blood Products Position Paper: Utilization and Inventory Management of Group O RH(D)- Negative Red Cells

Plasma Protein and Related Products Recommendations

  • Intravenous Immunoglobulin (IVIG)
  • NAC Statement on Clinical Equivalency of Select Fractionated Plasma Protein Products
  • NAC Statement on Factor XIII Concentrate Use
  • NAC Statement on Fibrinogen Concentrate Use in Acquired Hypofibrinogenemia
  • Recombinant Factor VIIa
  • Recommendations for Use of Prothrombin Complex Concentrates in Canada
  • Solvent Detergent Treated Plasma (S/D Plasma)

Special Testing / Modification Recommendations

  • Cytomegalovirus (CMV)
  • Recommendations for Use of Irradiated Blood Components in Canada
  • RHD Genotyping in Prenatal Patients
  • Supplement to the NAC-CCNMT Irradiation Recommendations

Adverse Event Recommendations

  • Adverse Reaction Reporting Mechanisms
  • Key Messages- Sentinel Event Communication and Reporting
  • Questions and Answers Briefing - Bill C-17: Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)
  • Recommendations for the Notification of Recipients of a Blood Component Recall
NAC Logo NAC Logo (English) NAC Logo (Français)
National Advisory Committee on Blood and Blood Products (NAC)

NAC

  • Blood Shortage
  • Endorsements
  • Guidelines & Recommendations
  • Links & Resources

Recently updated resources

  • NAC Recommendations for Solvent Detergent Plasma (S/D Plasma)
  • Recommendations for Use of Prothrombin Complex Concentrates in Canada
  • NAC Statement on the Introduction of Leukocyte Reduced Whole Blood in Canada
  • NAC Patient Blood Management Statement
  • Massive Transfusion Consensus Conference

Contact

NAC Chair

Alan Tinmouth

NAC Project Coordinator

Harleen Kahlon

ONBlood@ontario.ca

© Copyright 2023. National Advisory Committee on Blood and Blood Products. All rights reserved. Disclaimer & Privacy Info